© 2024 © 2020 Genprex Inc. All Rights Reserved.
Our technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options.
We are developing gene therapies for patients with cancer and diabetes to bring new therapies to large patient populations. Our lead product candidate, Reqorsa® Immunogene Therapy, is designed to be administered in combination with other therapies, including targeted therapies and immunotherapies, for non-small cell lung cancer and small cell lung cancer.
We have assembled a multidisciplinary team of executives and advisors with broad business experience in the biotech and pharmaceutical industries, and research and clinical experience at preeminent medical and academic institutions around the world. Our management team pairs an unmatched expertise with a knack for innovation in research.
At Genprex, we are committed to developing life-changing gene therapies for patients afflicted with cancer and diabetes. We are dedicated in our efforts to helping patients with limited or no treatment options to have access to new and advanced therapies to more effectively treat their disease.
Compelling Data Validates the Potential of Reqorsa® Immunogene Therapy and the Oncoprex® Delivery System as Innovative Cancer Treatments
Multiple clinical trial sites to be opened under collaboration with large network of community-based oncology practices
NPRL2 Gene Therapy Induces Anti-Tumor Activity in Anti-PD1 Resistant KRAS/STK11 Mutant Non-Small Cell Lung Cancer in a Humanized Mouse Model
Genprex Announces Closing of $6.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
We’re passionate about the work we’re doing to revolutionize the fight against cancer and diabetes. Whether you or somebody you know is afflicted by one of these diseases, you are a medical practitioner interested in our treatment options, or you are an investor that has supported our fight, we want to keep you informed of our advancements. For up-to-the-minute company news delivered straight to your inbox, sign up for our email newsletter.